BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30
• 31

• 

  15 Ways to be Happy at Work

  Some studies show that over half of all Americans are not happy with their jobs. What can be the reasons? How to be happy at work? Find solutions here.

  May 10, 2018

   · 

  4 min read
• 

  Business

  Genentech’s Tecentriq Flunks Phase III for Colorectal Cancer

  Genentech reported that its Phase III IMblaze370 trial of Tecentriq (atezolizumab) and Cotellic (cobimetinib) for difficult-to-treat, locally advanced or metastatic colorectal cancer (CRC) did not meet its primary endpoint of overall survival (OS) compared to Bayer’s Stivarga (regorafenib).

  May 10, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Newly Merged Amneal Pharmaceuticals to Push into the Biosimilar Space

  Earlier this week Amneal Pharmaceuticals and Impax Laboratories completed their business merger, forming the new Amneal Pharmaceuticals. The combined companies are now the fifth largest generics business in the United States.

  May 10, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Rhythm Pharmaceuticals Publishes Longer-Term Data on LEPR Deficiency Obesity Study

  As Boston-based Rhythm Pharmaceuticals moves its lead obesity treatment into a second Phase III trial, the company was bolstered by the publication of longer-term data from its Phase II study of setmelanotide in Nature Medicine.

  May 10, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Post-hoc Analysis Gives New Life to vTv’s Experimental Alzheimer’s Drug

  North Carolina-based vTv Therapeutics revealed some potential hope for Alzheimer’s patients from its Phase III azeliragon study despite the drug failing to meet primary endpoints in April.

  May 10, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  4 Ways the U.S. Biopharma Industry is Pushing Back on Biosimilars

  Europe began approving biosimilars in 2006. The U.S. has lagged behind, only starting to approve these copycat drugs in 2015. However, of the nine biosimilars approved in the U.S., only three are actually on the market because of barriers thrown up by the biopharma industry.

  May 10, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  May 11th Research Roundup: Some of the Top Research Stories of the Week

  There are plenty of great scientific research stories out this week. Here’s a look at just a few of them, such as pancreas cells to cure type 1 diabetes and failed clinical trials cast doubt on new immuno-oncology targets.

  May 10, 2018

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Eli Lilly Drops $1.6 Billion for Armo BioSciences and its Phase III Immuno-Oncology Drug

  Shares of Armo BioSciences have soared more than 67 percent in premarket trading after Eli Lilly announced it had struck a deal to acquire the company for $1.6 billion in an all cash deal.

  May 10, 2018

   · 

  2 min read

   · 

  Alex Keown
• Business

  Nuvo Pharmaceuticals™ Announces 2018 First Quarter Results

  Nuvo Pharmaceuticals Inc. is a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities

  May 10, 2018

   · 

  14 min read
• Drug Development

  Exelixis Provides Update on IMblaze370 Phase 3 Pivotal Trial of Atezolizumab and Cobimetinib in Patients With Heavily Pretreated Locally Advanced or Metastatic Colorectal Cancer

  The study did not meet its primary endpoint of improving overall survival versus regorafenib. Results will be submitted for presentation at an upcoming medical meeting.

  May 10, 2018

   · 

  15 min read